|
Case no | Preoperative DA dose and duration | PRL after initial DA (μg/L) | Tumor volume after initial DA (cm3)† | Indication for surgery | Surgery type | Tumor pathology features |
|
1 | N/A | N/A | N/A | Misdiagnosis, vision loss | Craniotomy, incomplete resection | Benign, diffuse PRL stain, no co-staining |
2 | Cab 2.5 mg/wk for 36 mos | 4,156 (19% increase) | N/A–not measured | DA resistance and intolerance, vision loss, tumor apoplexy | Transsphenoidal endoscopy, incomplete resection | Benign, diffuse PRL stain, no co-staining, Ki-67 1-2% Tumor fibrosis |
3 | Cab 1 mg/wk for 3 mos | 262 (76% decrease) | 39.4 (44% increase) | DA resistance, vision loss | Transsphenoidal using microscopy, incomplete resection | Benign, diffuse PRL stain, ACTH co-staining (No co-secretion) |
4 | Cab 1 mg/wk for 3 weeks | 172 (93% decrease) | 20.0 (12% decrease) | CSF leak, DA intolerance, vision loss | Transsphenoidal using microscopy, incomplete resection | Benign, diffuse PRL stain, GH and TSH co-staining (no co-secretion) |
5 | Cab 2 mg/wk for 2 weeks | 364 (47% decrease) | 37.2 (20% increase) | DA resistance, vision loss | Transsphenoidal endoscopy, incomplete resection | Benign, diffuse PRL stain, no co-staining |
6 | Cab 3.5 mg/wk for 18 mos | 5,754 (>56% decrease) | 27.4 (11% decrease) | DA resistance and intolerance | Transsphenoidal endoscopy, incomplete resection | Benign, diffuse PRL stain, no co-staining Tumor fibrosis |
7 | N/A | N/A | N/A | Misdiagnosis, vision loss | Craniotomy, incomplete resection | Benign, diffuse PRL stain, no co-staining |
8 | Cab 3.5 mg/wk for 10 mos | 1,917 (83% decrease) | 23.9 (49% decrease) | CSF leak, DA resistance and intolerance | Transsphenoidal endoscopy, incomplete resection | Benign, diffuse PRL stain, no co-staining, Ki-67 20% Tumor fibrosis |
|